These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 20636842)

  • 61. Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
    Feit F; Manoukian SV; Ebrahimi R; Pollack CV; Ohman EM; Attubato MJ; Mehran R; Stone GW
    J Am Coll Cardiol; 2008 Apr; 51(17):1645-52. PubMed ID: 18436116
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Short- and long-term outcomes in diabetes patients undergoing percutaneous coronary intervention with bivalirudin compared with heparin and glycoprotein IIb/IIIA inhibitors: A meta-analysis of randomized trials.
    Nairooz R; Sardar P; Amin H; Chatterjee S; Helmy T; Naidu SS
    Catheter Cardiovasc Interv; 2015 Sep; 86(3):364-75. PubMed ID: 25914388
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Angiographic and clinical outcomes of bivalirudin versus heparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Matar F; Donoghue C; Rossi P; Vandormael M; Sullebarger JT; Kerenski R; Jauch W; Gloer K; Ebra G
    Can J Cardiol; 2006 Nov; 22(13):1139-45. PubMed ID: 17102832
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Bivalirudin in percutaneous coronary intervention for chronic total occlusion: A single-center pilot study.
    Li C; Xu R; Shen Y; Dai Y; Zhang F; Ma J; Ge L; Qian J; Ge J
    Catheter Cardiovasc Interv; 2018 Mar; 91(4):679-685. PubMed ID: 28766879
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Bivalirudin versus heparin for percutaneous coronary intervention: an updated meta-analysis of randomized controlled trials.
    Lipinski MJ; Lhermusier T; Escarcega RO; Baker NC; Magalhães MA; Torguson R; Suddath WO; Satler LF; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2014; 15(6-7):315-22. PubMed ID: 25440505
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Safety and efficacy of bivalirudin with glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention.
    Deshpande NV; Pratiti R; Admane P; Mukherjee D; Mardikar HM
    Indian Heart J; 2012; 64(5):444-8. PubMed ID: 23102380
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry.
    Bangalore S; Pencina MJ; Kleiman NS; Cohen DJ
    Circ Cardiovasc Interv; 2014 Jun; 7(3):365-73. PubMed ID: 24736878
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome.
    Allie DE; Hebert CJ; Lirtzman MD; Wyatt CH; Keller VA; Khan MH; Khan MA; Fail PS; Vivekananthan K; Allie SE; Mitran EV; Chaisson G; Stagg SJ; Allie AA; McElderry MW; Barker EA; Walker CM
    J Invasive Cardiol; 2005 Aug; 17(8):427-32. PubMed ID: 16079449
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Safety and efficacy of bivalirudin monotherapy in patients with non-ST-segment elevation acute coronary syndromes with positive biomarkers undergoing percutaneous coronary intervention: a report from the Acute Catheterization and Urgent Intervention Triage Strategy trial.
    Huang X; Chen S; Redfors B; Zhang Y; Souza CF; Mehran R; Bansilal S; Kirtane AJ; Brener SJ; Feite F; Dangas GD; Ben-Yehuda O; Stone GW
    Coron Artery Dis; 2020 Jan; 31(1):59-65. PubMed ID: 31809479
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Safety of bivalirudin in percutaneous coronary intervention following thrombolytic therapy.
    Sardi GL; Lindsay J; Waksman R
    Catheter Cardiovasc Interv; 2013 Oct; 82(4):614-20. PubMed ID: 22581418
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy and safety of bivalirudin versus heparins in reduction of cardiac outcomes in acute coronary syndrome and percutaneous coronary interventions.
    Singh S; Molnar J; Arora R
    J Cardiovasc Pharmacol Ther; 2007 Dec; 12(4):283-91. PubMed ID: 18172222
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial).
    Lincoff AM; Bittl JA; Kleiman NS; Sarembock IJ; Jackman JD; Mehta S; Tannenbaum MA; Niederman AL; Bachinsky WB; Tift-Mann J; Parker HG; Kereiakes DJ; Harrington RA; Feit F; Maierson ES; Chew DP; Topol EJ;
    Am J Cardiol; 2004 May; 93(9):1092-6. PubMed ID: 15110198
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Bivalirudin is associated with improved clinical and economic outcomes in heart failure patients undergoing percutaneous coronary intervention: Results from an observational database.
    Pinto DS; Kohli P; Fan W; Kirtane AJ; Kociol RD; Meduri C; Deliargyris EN; Prats J; Reynolds MR; Stone GW; Michael Gibson C
    Catheter Cardiovasc Interv; 2016 Feb; 87(3):363-73. PubMed ID: 26011467
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Bivalirudin started during emergency transport for primary PCI.
    Steg PG; van 't Hof A; Hamm CW; Clemmensen P; Lapostolle F; Coste P; Ten Berg J; Van Grunsven P; Eggink GJ; Nibbe L; Zeymer U; Campo dell' Orto M; Nef H; Steinmetz J; Soulat L; Huber K; Deliargyris EN; Bernstein D; Schuette D; Prats J; Clayton T; Pocock S; Hamon M; Goldstein P;
    N Engl J Med; 2013 Dec; 369(23):2207-17. PubMed ID: 24171490
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes.
    Gargiulo G; Carrara G; Frigoli E; Vranckx P; Leonardi S; Ciociano N; Campo G; Varbella F; Calabrò P; Garducci S; Iannone A; Briguori C; Andò G; Crimi G; Limbruno U; Garbo R; Sganzerla P; Russo F; Lupi A; Cortese B; Ausiello A; Ierna S; Esposito G; Zavalloni D; Santarelli A; Sardella G; Tresoldi S; de Cesare N; Sciahbasi A; Zingarelli A; Tosi P; van 't Hof A; Omerovic E; Brugaletta S; Windecker S; Valgimigli M
    J Am Coll Cardiol; 2018 Mar; 71(11):1231-1242. PubMed ID: 29544607
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Outcomes of patients with prior coronary artery bypass grafting and acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
    Nikolsky E; McLaurin BT; Cox DA; Manoukian SV; Xu K; Mehran R; Stone GW
    JACC Cardiovasc Interv; 2012 Sep; 5(9):919-26. PubMed ID: 22995879
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin Versus Heparin: A Report From the National Cardiovascular Data Registry.
    Jovin IS; Shah RM; Patel DB; Rao SV; Baklanov DV; Moussa I; Kennedy KF; Secemsky EA; Yeh RW; Kontos MC; Vetrovec GW
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1102-1111. PubMed ID: 28527778
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Benefit of bivalirudin versus heparin after transradial and transfemoral percutaneous coronary intervention.
    MacHaalany J; Abdelaal E; Bataille Y; Plourde G; Duranleau-Gagnon P; Larose É; Déry JP; Barbeau G; Rinfret S; Rodés-Cabau J; De Larochellière R; Roy L; Costerousse O; Bertrand OF
    Am J Cardiol; 2012 Dec; 110(12):1742-8. PubMed ID: 22980964
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison of antithrombotic agents during urgent percutaneous coronary intervention following thrombolytic therapy: A retrospective cohort study.
    Mallidi JR; Robinson P; Visintainer PF; Lotfi AS; Mulvey S; Giugliano GR
    Catheter Cardiovasc Interv; 2017 Nov; 90(6):898-904. PubMed ID: 28417608
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparative cost-effectiveness of anticoagulation with bivalirudin or heparin with and without a glycoprotein IIb/IIIa-receptor inhibitor in patients undergoing percutaneous coronary intervention in Sweden: a decision-analytic model.
    Borg S; Persson U; Allikmets K; Ericsson K
    Clin Ther; 2006 Nov; 28(11):1947-59. PubMed ID: 17213015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.